Lupus nephritis (LN)

This phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…

This early-phase trial tests whether a single infusion of CD19 CAR-T cells, called TranspoCART19, is safe and can push severe lupus nephritis into remission. Lupus nephritis is a serious kidney complication of lupus that often resists standard treatments. Ten adults with refracto…

This study evaluates a new care model for people with lupus nephritis, a kidney complication of lupus. The approach uses telemedicine visits and clinical pharmacist practitioners to provide medication support, adherence help, and remote monitoring, with oversight from specialists…

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…

Lupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…

This study looks at whether two simple blood test ratios—neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein to serum albumin ratio (CAR)—can predict which hospitalized adults with lupus nephritis will need intensive care or die during their stay. Researchers will compare…

This study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…